Sign in

Alzheimer disease

Current status: No cure yet

A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.

Read more about Alzheimer disease
Where research stands todayUpdated 16 Nov 2026

Trial-stage treatments and research studies you can join

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsPoland, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Long-Term Safety Study of KarXT for Psychosis in Alzheimer's Disease

    Tests KarXT, a long-term safety study in people with Alzheimer's-related psychosis.

    Gdansk, PolandAlso Katowice, Lodz, Lublin, Poznan, SochaczewAge 55 to 90
  2. Trial-stage treatmentPhase 2Taking people
    Tests ML-007C-MA for hallucinations and delusions in Alzheimer's disease psychosis

    Tests ML-007C-MA against placebo in people with Alzheimer's psychosis.

    Gdansk, PolandAlso Krakow, Lublin, Plewiska, PoznanAge 55 to 90
  3. Trial-stage treatmentPhase 3Taking people
    Long-term study of KarXT and KarX-EC for agitation in Alzheimer's disease

    Tests KarXT and KarX-EC over time in people with Alzheimer's-related agitation.

    Bydgoszcz, PolandAlso Chorzow, Poznan, SochaczewAge 55 to 90
  4. Trial-stage treatmentPhase 2Soon in Poland
    Long-term safety of ML-007C-MA for hallucinations and delusions in Alzheimer's disease

    Tests ML-007C-MA over 52 weeks in adults with Alzheimer's disease psychosis.

    Gdansk, PolandAlso Krakow, Plewiska, Poznan, WarsawAge 55 to 91
  5. Trial-stage treatmentPhase 2/3Taking people
    EXV-802 and EXV-801 for agitation in people with Alzheimer's disease dementia

    Tests EXV-802 and EXV-801 against placebo for agitation in Alzheimer's disease dementia.

    Katowice, PolandAlso Lublin, Poznan, Sochaczew, Staszow, Warsaw, Wroclaw, ZabrzeAge 55 to 90
  6. Trial-stage treatmentPhase 2Taking people
    Tests RO7568282 against a placebo in early Alzheimer's disease

    Compares RO7568282 with a placebo in people in early Alzheimer's disease.

    Bydgoszcz, PolandAlso Szczecin, Warsaw, WroclawAge 50 to 90
  7. Trial-stage treatmentPhase 2
    Tests ITI-1284 for psychosis in people with Alzheimer's disease

    Compares ITI-1284 with placebo for psychosis in adults with Alzheimer's disease.

    Bydgoszcz, PolandAlso Katowice, ŚcinawaAge 55+
  8. Trial-stage treatmentPhase 3Taking people
    Tests KarXT with KarX-EC for agitation in Alzheimer's disease

    Tests KarXT with KarX-EC against placebo in adults with Alzheimer's-related agitation.

    Bydgoszcz, PolandAlso Chorzow, Poznan, SochaczewAge 55 to 90
  9. Trial-stage treatmentPhase 3Taking people
    KarXT Tested for Psychosis in People With Alzheimer's Disease

    Tests KarXT against placebo in adults with Alzheimer's and psychosis.

    Gdansk, PolandAlso Lodz, Lublin, Poznan, SochaczewAge 55 to 90
  10. Trial-stage treatmentPhase 3Taking people
    Testing KarXT with KarX-EC for memory problems in Alzheimer's disease

    Tests KarXT with KarX-EC against placebo in adults with mild to moderate Alzheimer's disease.

    Gdansk, PolandAlso PoznanAge 60 to 85
  11. Trial-stage treatmentPhase 3Taking people
    Tests KarXT with KarX-EC for memory and thinking problems in Alzheimer's disease

    Tests KarXT with KarX-EC against a placebo in people with mild to moderate Alzheimer's.

    Katowice, PolandAlso Oswiecim, WroclawAge 60 to 85
  12. Trial-stage treatmentPhase 2Taking people
    Tests dimethyl fumarate for memory and thinking in early Alzheimer's disease

    Tests dimethyl fumarate against placebo in adults with mild cognitive impairment or early Alzheimer's.

    Lodz, PolandAge 55 to 90
  13. Research studyTaking people
    Long-Term Registry Following People With Alzheimer's and Related Dementias

    Collects routine clinical information from adults with Alzheimer's disease over many years.

    Warsaw, PolandAge 18+
  14. Trial-stage treatmentPhase 3
    Screening people with Alzheimer's disease for possible future studies

    Checks whether adults with Alzheimer's disease may qualify for later research studies.

    Bydgoszcz, PolandAlso Gdansk, Katowice, Krakow, Lublin, Późna, Rzeszów, Ścinawa, Sopot, …Age 50 to 90
  15. Trial-stage treatmentTaking people
    Neck Lymphatic Microsurgery for People With Mild Alzheimer's Disease

    Tests neck lymphatic microsurgery in adults with mild Alzheimer's disease.

    Gdansk, PolandAlso SłupskAge 18+
  16. Trial-stage treatmentPhase 2
    Tests ITI-1284 for psychosis in people with Alzheimer's disease

    Tests a daily pill against a placebo for psychosis in adults with Alzheimer's.

    Bydgoszcz, PolandAge 18+

Where treatment stands

In the EU, lecanemab was first approved in April 2025 and donanemab in September 2025.

Approved: 12

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 29

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 5

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Lab research stage: 1

Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.

Words used here

Placebo: a dummy treatment without the medicine, used for comparison.

Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.

Where this comes from

The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.

A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.

The EU medicines agency (EMA), ClinicalTrials.gov and the EU trials register, checked on 10 November 2026. Every treatment links to its own records; the texts are written by AI from them.

Medicines approved only in single countries are not included. We did not check in which countries a medicine is sold or paid for. Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 99 other open phase 2 trials are not listed.

Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for Alzheimer's disease. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.

Not medical advice. Talk to your doctor before you change any treatment.

The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.

Support organisations

Patient organisations and helplines in Poland, for you and your family.

Alzheimer disease organisations in Poland

  • Polskie Stowarzyszenie Pomocy Osobom z Choroba Alzheimera

    Warsaw association: helpline and consultations (Tue and Thu 15-17), support and self-help groups, conferences and patient forum.

General support in Poland

  • Centrum Wsparcia dla osób dorosłych w kryzysie psychicznym

    Free 24/7 support line (800 70 2222) and chat for adults in psychological crisis in Poland, funded by the Ministry of Health.

  • pacjent.gov.pl

    Patient portal of the Polish Ministry of Health and National Health Fund with reliable, verified information on health and the care system.

  • Rzecznik Praw Pacjenta

    Poland's central government Patient Ombudsman protecting patient rights, with a free patient helpline (800 190 590).

International organisations

  • Alzheimer's Association

    Free 24/7 Helpline (interpreters for 200+ languages), care consultations with dementia experts, local chapters, Community Resource Finder, ALZConnected online community.

  • Alzheimer's Drug Discovery Foundation

    Funds the early work on new Alzheimer's medicines, in universities and companies.

  • BrightFocus Foundation

    US nonprofit that funds research and provides public information on Alzheimer's disease, macular degeneration and glaucoma.

  • Dementia Alliance International (DAI)

    Organisation for people with a dementia diagnosis: free online peer support groups, webinars, Brain Health Hub, resources for care partners.

Patient organisation umbrella bodies

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.No open programme yet
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

12 medicines are approved for Alzheimer disease in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 11 Nov 2026 in the official lists of the US (FDA), the EU (EMA), Japan (PMDA, approvals since April 2004), Switzerland (Swissmedic), France (ANSM, medicines approved in France only) and Taiwan (TFDA). For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. 4 uncertain matches are left out. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste what you read here, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

“Cures” others already fact-checked

See all 4

About Alzheimer disease

Sources: NHS, MedlinePlus, Archives of Neurology

A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.

What is it?

Alzheimer's is the most common cause of dementia: a steady loss of memory, thinking and other mental abilities. Proteins build up in and around brain cells. One protein (amyloid) forms clumps around the cells, another (tau) forms tangles inside them. Over time parts of the brain shrink, usually the memory areas first. These changes begin many years before any signs. It is not a normal part of getting older.

Most people who get it are over 65, and the risk rises with age: about 1 in 14 people over 65 and 1 in 6 over 80 have Alzheimer's or another type of dementia. Genes usually raise the risk only a little. In a few families a single gene causes it, and then it is much more likely to be passed on.

The first signs

The signs come on slowly over several years and are sometimes taken for normal ageing.

  • forget recent conversations or events;
  • misplace things and forget the names of places and objects;
  • struggle to find the right word, or ask the same questions again and again;
  • find decisions harder and become more hesitant about trying new things;
  • feel anxious, agitated or confused at times.

How doctors find out

There is no simple, reliable test. The doctor checks your general health, may order blood tests and ask about your medicines to rule out other causes, and asks you to do some memory and thinking tasks. You may then be sent to a specialist, who may work at a memory clinic, for more tests such as a brain scan (CT or MRI). Finding out can take many months and several appointments.

Current treatment

Symptom medicines (e.g. donepezil) plus support

Will it get worse?

Yes. It is a progressive illness: the symptoms get worse slowly over several years. It gets worse slowly, at a different pace for each person. In the middle stage people usually need support with everyday living, such as help with eating, washing, getting dressed and using the toilet. In the severe stages they may need full-time care. People may live for several years after the signs begin, but this varies a lot. Alzheimer's shortens life, though many people with it die of something else.

Medicines: what helps, and what to watch for

Medicines cannot cure Alzheimer's, but some can ease the symptoms for a time. Donepezil, galantamine and rivastigmine raise acetylcholine, a brain chemical that helps nerve cells pass messages; they are used in the early and middle stages. Memantine works in a different way and is used when the disease is moderate or severe.

Good to know:

  • specialists, such as psychiatrists or neurologists, can prescribe these medicines; your family doctor may prescribe them on a specialist's advice;
  • feeling sick, being sick and losing your appetite can be side effects, and they usually get better after about 2 weeks;
  • memantine can cause headaches, dizziness and constipation, which usually pass;
  • for aggression or extreme distress, other ways of coping are tried first; antipsychotic medicines have serious side effects, so they should be used at the lowest dose for the shortest time possible.

Exercise and therapy help too

Some treatments without medicines can help memory, problem solving, mood and wellbeing:

  • cognitive stimulation therapy: group activities and exercises for memory and problem solving;
  • cognitive rehabilitation: working with a professional, such as an occupational therapist, and a relative or friend towards a personal goal, like using a mobile phone;
  • reminiscence and life story work: talking about the past with the help of photos, objects or music.

Exercise regularly, for example with a daily walk, gardening, tai chi or dancing.

Is there a cure?

Not yet. No treatment can stop the disease today.

See the 898 trials you can join

Median survival

About 3 to 8 years after diagnosis, depending on age at diagnosis

Measured in: Participants of the Baltimore Longitudinal Study of Aging older than 55, followed 1985–1999

The figures behind it

Baltimore Longitudinal Study of Aging (participants older than 55, followed 1985–1999): median survival 8.3 years when Alzheimer disease was diagnosed at age 65, down to 3.4 years when it was diagnosed at age 90; no significant difference between men and women.